SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting - 2Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- 3Turkey’s intel chief lays out country’s vision for Middle East, world
- 4Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- 5The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- See the famous winged horse Pegasus fly in the autumn night sky
- The Delight of Perusing: Book Proposals for Each Class
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- Vote in favor of the subject that you see as generally captivating and intelligent!
- Zelensky sees new Russian attack threat from Belarus
- AfD in Brandenburg takes back suit against the intelligence service
- New India programme supports tribal families hosting tourists
- Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
